Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Total Non-current Assets
All assets not expected to be converted to cash within one year.
Biogen Inc.NASDAQ: BIIB
Total Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Total non-current assets rises 21.7% from a year ago
Total non-current assets stood at $24.78B at the end of Q2 FY2026, up 21.7% from a year earlier and up 22.1% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Total non-current assets amounted to 77.2% of total assets at the end of Q2 FY2026, up 5.4 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +21.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 20.47B USD
- Year-over-year change
- -0.6%
- 4-year CAGR
- +6.3%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.47B | -0.6% |
| FY2024 | 2024-12-31 | 20.59B | +3.0% |
| FY2023 | 2023-12-31 | 19.99B | +35.4% |
| FY2022 | 2022-12-31 | 14.76B | -7.9% |
| FY2021 | 2021-12-31 | 16.02B | — |
Total Non-current Assets vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's Jun 2026 total non-current assets of $24.78B is the 5th highest of the 11 companies compared; the peer median is $22.17B.
- Its year-over-year change of +21.7% is the 4th highest of 11, against a peer median of +5.8%.
- Total non-current assets amounts to 77.2% of total assets for BIIB, versus a peer median of 55.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $159.77B | -1.6% | +4.2% | 79.4% | |
| Sep 2026 | $88.32B | +4.5% | +4.9% | 73.8% | |
| Jun 2026 | $77.61B | +52.0% | +21.8% | 54.5% | |
| Jun 2026 | $60.68B | -0.8% | +12.7% | 63.4% | |
| Jun 2026 | $24.78B | +21.7% | +11.5% | 77.2% | |
| Jun 2026 | $23.28B | +9.0% | +19.1% | 55.8% | |
| Sep 2026 | $21.05B | +47.3% | +44.9% | 64.3% | |
| Jun 2026 | $3.74B | -8.4% | +16.2% | 51.7% | |
| Jun 2026 | $938.6M | +1.8% | +2.3% | 16.9% | |
| Jun 2026 | $633.12M | +75.2% | -14.8% | 19.5% | |
| Sep 2026 | $551.09M | +7.2% | +17.2% | 18.9% | |
| Peer median (excluding BIIB) | $22.17B | +5.8% | +14.5% | 55.2% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.26B | 3.42B | 1.05B | 2.38B | 3.01B |
| Short-term Investments | 1.54B | 1.47B | 0 | 0 | 807.2M |
| Net Receivables | 1.96B | 2.14B | 2.1B | 1.87B | 1.87B |
| Inventory | 1.35B | 1.34B | 2.53B | 2.46B | 2.17B |
| Other Current Assets | 740.8M | 1.42B | 1.18B | 752.5M | 1.12B |
| Total Current Assets | 7.86B | 9.79B | 6.86B | 7.46B | 8.97B |
| Property, Plant & Equipment (Net) | 3.79B | 3.7B | 3.73B | 3.54B | 3.32B |
| Goodwill | 5.76B | 5.75B | 6.22B | 6.48B | 6.49B |
| Intangible Assets | 2.22B | 1.85B | 8.36B | 9.69B | 9.18B |
| Long-term Investments | 892M | 705.7M | 460.7M | 226.7M | 750.6M |
| Tax Assets | 1.42B | 1.23B | 928.6M | 324.2M | 292.5M |
| Other Non-current Assets | 1.94B | 1.53B | 284.3M | 333.8M | 431.9M |
| Total Non-current Assets | 16.02B | 14.76B | 19.99B | 20.59B | 20.47B |
| Total Assets | 23.88B | 24.55B | 26.84B | 28.05B | 29.44B |
| Account Payables | 589.2M | 491.5M | 403.3M | 424.2M | 432M |
| Short-term Debt | 999.1M | 0 | 150M | 1.75B | 80.4M |
| Tax Payables | 174.7M | 259.9M | 257.4M | 548.3M | 114.8M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 345.1M | 1.14B | 335.1M | 375.8M | 2.72B |
| Total Current Liabilities | 4.3B | 3.27B | 3.43B | 5.53B | 3.35B |
| Long-term Debt | 6.27B | 6.28B | 6.79B | 4.55B | 6.58B |
| Deferred Tax Liabilities | 694.5M | 334.7M | 641.8M | 190.5M | 507.6M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.32B | 944.2M | 781.1M | 732.3M | 458.1M |
| Total Non-current Liabilities | 8.62B | 7.89B | 8.61B | 5.8B | 7.83B |
| Total Liabilities | 12.92B | 11.17B | 12.05B | 11.33B | 11.18B |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 13.91B | 16.47B | 17.63B | 19.26B | 20.55B |
| Accumulated OCI | (106.7M) | (164.9M) | (153.7M) | (136.2M) | (182M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 63.5M | (9.5M) | 0 | 0 | 0 |
| Total Equity | 10.96B | 13.39B | 14.8B | 16.72B | 18.26B |
| Total Debt | 7.6B | 6.61B | 7.34B | 6.63B | 6.95B |
| Net Debt | 5.34B | 3.19B | 6.29B | 4.26B | 3.94B |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.